Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.48 |
| ▸ | PFKFB4 | Q16877 | 1/20 | 0.45 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | ACP1 | P24666 | 1/20 | 0.41 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL496572 | 0.86 | MAPT (0.52) | PFKFB4PFKFB3CSNK2A1 | |
| SCHEMBL496631 | 0.86 | KDR (0.46) | KDRMETPDGFRBKITFLT1 | |
| SCHEMBL497262 | 0.83 | KDR (0.53) | KDRMETPDGFRBKITFLT1 | |
| SCHEMBL496935 | 0.80 | KDR (0.52) | KDRACP1PDGFRBKITFLT1 | |
| SCHEMBL496555 | 0.79 | KDR (0.48) | KDRMETPDGFRBKITFLT1 | |
| SCHEMBL496594 | 0.77 | KDR (0.46) | KDRPDGFRBKITFLT1ALDH1A1 | |
| SCHEMBL496898 | 0.77 | MAPT (0.55) | — | |
| SCHEMBL496493 | 0.74 | MAPT (0.43) | MET | |
| SCHEMBL1249303 | 0.73 | PFKFB4 (0.61) | PFKFB4PFKFB3PTGDRPTGDR2ALDH1A1 | |
| SCHEMBL2028971 | 0.72 | PDE2A (0.56) | KDRALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | claimed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | claimed |
| EP-1836207-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2007-09-26 | — | — | EP | claimed |
| WO-2006072615-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | claimed |
| EP-1836207-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| EP-1836207-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072615-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312225-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | KDR 1477/4885PFKFB4 1969/4885PFKFB3 1799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.